Multi-Strain Probiotic Lysate Attenuates TGF-β1-Induced Intestinal Fibrosis and EMT Modulating Smad, Akt, and WNT/β-Catenin Pathways
Authors:
- Alessia CiafaroneACAlessia Ciafarone
- Serena ArtoneSASerena Artone
- Valeria CiummoVCValeria Ciummo
- Francesca Rosaria AugelloFAFrancesca Rosaria Augello
- Serena AltamuraSerena Altamura
- Francesca LombardiFrancesca Lombardi
- Giovanni LatellaGLGiovanni Latella
- Paola PalumboPaola Palumbo
- Benedetta CinqueBCBenedetta Cinque
Open Access
Abstract
Intestinal fibrosis is a common complication of inflammatory bowel diseases (IBD), and, to date, effective and safe antifibrotic drugs are still lacking. Emerging evidence suggests that probiotics may provide novel strategies to counteract fibrotic processes. In this study, we evaluated the anti-fibrotic potential of a multi-strain probiotic formulation, OxxySlabTM, using in vitro models of intestinal fibrosis and epithelial-to-mesenchymal transition (EMT). Human intestinal fibroblasts (CCD-18Co cell line) and epithelial cells (Caco-2 cell line, IECs) were stimulated with transforming growth factor-β1 (TGF-β1) to induce fibrotic and EMT phenotypes, respectively. Treatment with OxxySlab modulated cell proliferation and fibrosis-related markers, which we assessed through CCK-8 assay, Western blotting, and immunofluorescence. The probiotic lysate inhibited both canonical and non-canonical TGF-β1 signaling pathways, and it also reduced TGF-β1 gene expression in activated myofibroblasts, as shown by RT-qPCR. Furthermore, probiotic treatment reversed EMT features by restoring epithelial markers and downregulating mesenchymal markers. These findings highlight the beneficial effects of the multi-strain probiotic formulation as an adjunctive therapeutic agent targeting key pathways involved in intestinal fibrosis.Keywords
Funding Information
- Department of Life, Health, and Environmental Sciences, University of L’Aquila (FFO MeSVA 2025)
This publication has 78 references indexed in Scilit:
- Wnt/β-catenin signalling, epithelial-mesenchymal transition and crosslink signalling in colorectal cancer cellsBiomedicine & Pharmacotherapy, 2024
- Probiotics, prebiotics, and postbiotics in health and diseaseMedcomm, 2023
- The Current and Future Perspectives of PostbioticsProbiotics and Antimicrobial Proteins, 2023
- Gut microbiota modulation in Alzheimer's disease: Focus on lipid metabolismClinical Nutrition, 2022
- Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosisActa Pharmaceutica Sinica B, 2021
- Role of PI3K/Akt signaling pathway in cardiac fibrosisMolecular and Cellular Biochemistry, 2021
- The Unregulated Probiotic MarketClinical Gastroenterology and Hepatology, 2019
- SLAB51 Probiotic Formulation Activates SIRT1 Pathway Promoting Antioxidant and Neuroprotective Effects in an AD Mouse ModelMolecular Neurobiology, 2018
- The Impact of Food Bioactives on Health2015
- Inflammatory bowel disease: an impaired barrier diseaseLangenbeck's Archives of Surgery, 2012